Teva Pharmaceutical Industries Ltd, ADR (TEVA)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

5 BAZEL ST PETACH TIKVA, ISRAEL 49131

Teva Pharmaceutical Industries Ltd (Teva) is an Israel-based pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Tevas active pharmaceutical ingredient (API) business provides vertical integration to Tevas own pharmaceutical production. The Companys global operations are conducted from North and Latin America to Europe and Asia. Teva operates a number of subsidiaries in such countries as Canada, Croatia, the Czech Republic, France, Germany, Hungary, Ireland, Israel, Japan, Poland, the Russian Federation, Spain, the Netherlands, the United Kingdom and the United States.

Data based on most recent fiscal year report
Market Cap17.236 Billion Shares Outstanding1.017 Billion Avg Volume25.904 Million
1-Yr BETA vs S&P TR1.602 Current Ratio0.86 Quick Ratio0.58
View SEC Filings from TEVA instead.

View recent insider trading info

Funds Holding TEVA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding TEVA BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

6.8 Thousand total shares from 2 transactions

Exercise Derivative Conversion (M)

12.8 Thousand total shares from 2 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

FRIDRIKSDOTTIR HAFRUN EXECUTIVE VP, GLOBAL R&D

  • Officer
22,754 2019-12-31 6

KALIF ELIYAHU SHARON EVP, CHIEF FINANCIAL OFFICER

  • Officer
0 2019-12-22 1

BARER SOL J

  • Director
0 2019-12-05 4

MCCLELLAN MICHAEL JAMES EVP, CHIEF FINANCIAL OFFICER

  • Officer
15,898 2019-11-05 5

SCHULTZ KARE PRESIDENT AND CEO

  • Officer
  • Director
63,613 2019-11-03 2

DRAPE ERIC EXECUTIVE VP GLOBAL OPERATIONS

  • Officer
17,195 2019-10-02 1

DANIELL RICHARD EXEC. VP, EUROPEAN COMMERCIAL

  • Officer
1,676 2019-09-18 6

DETHLEFS SVEN EVP GLOBAL MARKETING&PORTFOLIO

  • Officer
10,595 2019-09-18 5

GRIFFIN DEBORAH A CHIEF ACCOUNTING OFFICER

  • Officer
0 2019-09-18 5

NAZZI GIANFRANCO EVP, GROWTH MARKETS COMMERCIAL

  • Officer
10,678 2019-09-18 5

O'GRADY BRENDAN P. EVP, NORTH AMERICA COMMERCIAL

  • Officer
2,135 2019-09-18 5

CRANE ROSEMARY A

  • Director
8,543 2019-08-22 2

GREENE-SULZBERGER GABRIELLE

  • Director
1,621 2019-06-25 0

ELSTEIN AMIR

  • Director
0 2019-06-11 2

GOLDBERG MURRAY A

  • Director
0 2019-06-11 1

HALFON JEAN MICHEL

  • Director
0 2019-06-11 2

LIEBERMAN GERALD M

  • Director
0 2019-06-11 2

MIGNONE ROBERTO

  • Director
0 2019-06-11 1

NISEN PERRY

  • Director
0 2019-06-11 1

PERES NECHEMIA JACOB

  • Director
0 2019-06-11 1

SATCHI-FAINARO RONIT

  • Director
0 2019-06-11 1

DE NOTARISTEFANI CARLO EXECUTIVE VP GLOBAL OPERATIONS

  • Officer
33,589 2019-05-18 5

STARK DAVID MATTHEW EXEC. VP CHIEF LEGAL OFFICER

  • Officer
2,974 2019-03-17 4

CODNER IRIS BECK EVP GLOBAL BRAND&COMMUNICATION

  • Officer
0 2019-03-04 3

SABAG MARK EVP, GLOBAL HUMAN RESOURCES

  • Officer
0 2019-03-04 3

SUESSKIND DAN S

  • Director
318,836 2018-01-19 0

MAOR GALIA

  • Director
0 2018-01-01 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

FRIDRIKSDOTTIR HAFRUN - Officer EXECUTIVE VP, GLOBAL R&D

2019-12-31 M 4,640 d 0 22,753.51 direct

FRIDRIKSDOTTIR HAFRUN - Officer EXECUTIVE VP, GLOBAL R&D

2019-12-31 S 2,459 $9.92 d 22,754 22,753.51 direct yes

FRIDRIKSDOTTIR HAFRUN - Officer EXECUTIVE VP, GLOBAL R&D

2019-12-31 M 4,640 a 25,213 22,753.51 direct

FRIDRIKSDOTTIR HAFRUN - Officer EXECUTIVE VP, GLOBAL R&D

2019-12-02 S 4,310 $10.49 d 20,573 20,572.51 direct yes

FRIDRIKSDOTTIR HAFRUN - Officer EXECUTIVE VP, GLOBAL R&D

2019-11-30 M 8,133 a 24,883 20,572.51 direct

FRIDRIKSDOTTIR HAFRUN - Officer EXECUTIVE VP, GLOBAL R&D

2019-11-30 M 8,133 d 0 20,572.51 direct
Click here to report any possible errors with this stock listing.

Elevate your investments